tiprankstipranks
Trending News
More News >
Nanobiotix Sa ADR (NBTX)
:NBTX
US Market
Advertisement

Nanobiotix (NBTX) Drug Pipeline

Compare
91 Followers
Drug Name
Condition
Stage
Status
Study Name
Trial Start Date
Article
Pembrolizumab, Nivolumab, Nbtxr3, Sabr
Metastatic Nsclc, Metastatic Renal Cell Carcinoma, Squamous Cell Carcinoma Of Head And Neck, Immunotherapy, Metastatic Triple-Negative Breast Carcinoma, Radiotherapy, Microsatellite Instability-High Solid Malignant Tumour, Metastasis From Malignant Tumor Of Liver, Metastasis From Malignant Tumor Of Cervix, Metastasis From Malignant Melanoma Of Skin (Disorder), Metastasis From Malignant Tumor Of Bladder (Disorder)
Phase I
Active Not Recruiting
NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy
Apr 10, 2018

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
    What is a clinical trial?
    A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
      What drugs does Nanobiotix Sa ADR (NBTX) have in its pipeline
      NBTX is currently developing the following drugs: Pembrolizumab, Nivolumab, Nbtxr3, Sabr. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
        What am I Missing?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis